<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305602</url>
  </required_header>
  <id_info>
    <org_study_id>CV-201</org_study_id>
    <nct_id>NCT02305602</nct_id>
  </id_info>
  <brief_title>A Study of VentriGel in Post-MI Patients</brief_title>
  <official_title>A Phase I, Open-label Study of the Effects of Percutaneous Administration of an Extracellular Matrix Hydrogel, VentriGel, Following Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ventrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ventrix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I, open label, study will investigate the effects of VentriGel injection in&#xD;
      patients who have experienced a first, large ST elevation myocardial infarction (STEMI)&#xD;
      treated by PCI within the past 3 years and have evidence of left ventricular remodeling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the safety and feasibility of VentriGel delivered trans-endocardially to subjects&#xD;
      with left ventricular ejection fraction (LVEF) 25 to 45% secondary to MI. Secondary endpoints&#xD;
      will look at efficacy variables of ESV, EDV, EF, scar mass.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">September 5, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse events that occur within 6 months of injection</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Failure</condition>
  <condition>Left Ventricular Remodeling</condition>
  <arm_group>
    <arm_group_label>Post Myocardial Infarction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VentriGel</intervention_name>
    <description>VentriGel will be injected via MyoStar catheter after NOGA mapping</description>
    <arm_group_label>Post Myocardial Infarction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is 30-75 years of age&#xD;
&#xD;
          2. The subject must be able to provide informed consent&#xD;
&#xD;
          3. At least 60 days and no more than 3 years will have passed since the first ST&#xD;
             elevation myocardial infarction (Index STEMI) at time of VentriGel administration&#xD;
&#xD;
          4. The Index STEMI must meet the following criteria:&#xD;
&#xD;
               1. First time diagnosis of STEMI AND;&#xD;
&#xD;
               2. Meet the STEMI criteria of the American College of Cardiology (ACC)/American&#xD;
                  Heart Association (AHA) (e.g. ST elevation in at least 2 contiguous leads &gt;0.2 mV&#xD;
                  in V1, V2 or V3 and/or &gt;0.1mV in at least two other leads), or new left bundle&#xD;
                  branch block (LBBB)&#xD;
&#xD;
          5. Evidence of left ventricular remodeling secondary to the myocardial infarction using&#xD;
             2-D echocardiography or cMR;&#xD;
&#xD;
               1. the LVEF must be ≥ 25% and ≤ 45% AND;&#xD;
&#xD;
               2. The left ventricular wall thickness is ≥ 8 mm in target area.&#xD;
&#xD;
          6. Successful percutaneous coronary intervention (PCI) restoring TIMI II of higher flow&#xD;
             to infarcted area&#xD;
&#xD;
          7. Negative pregnancy test [serum human chorionic gonadotropin (βhCG)] in women of&#xD;
             childbearing potential within 24 hours prior to dosing) or if less than 2 years&#xD;
             postmenopausal agree to use of adequate contraception during the study.&#xD;
&#xD;
          8. Must be ambulatory, willing and able to comply with protocol, including follow-up&#xD;
             visits&#xD;
&#xD;
          9. Subject must be receiving best medical treatment for their post-MI clinical&#xD;
             presentation according to the American College of Cardiology (ACC)/American Heart&#xD;
             Association (AHA) guidelines&#xD;
&#xD;
         10. For those subjects indicated for heart failure medical therapy, subjects must be on&#xD;
             stable therapy including beta-blockers and angiotensin converting enzyme inhibitors,&#xD;
             if tolerated, for at least 45 days prior to therapy delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to cardiac MR&#xD;
&#xD;
          2. NYHA Functional Classification 4 heart failure within the prior 6 months.&#xD;
&#xD;
          3. Significant coronary artery stenosis that may require percutaneous or surgical&#xD;
             revascularization within six months of enrollment, as determined by the principal&#xD;
             investigator&#xD;
&#xD;
          4. Left ventricular thrombus, left ventricular aneurysm, subjects with post-infarction&#xD;
             pericarditis, or subjects with wall motion abnormalities outside the region of the&#xD;
             infarct related artery&#xD;
&#xD;
          5. Frequent, recurrent, sustained (&gt;30 seconds) ventricular tachycardia in 30 days prior&#xD;
             to VentriGel administration&#xD;
&#xD;
          6. ECG or 24 hour Holter Monitor with any of the following findings:&#xD;
&#xD;
               -  Bifascicular block (left bundle branch block or right bundle branch block plus&#xD;
                  left hemi-block)&#xD;
&#xD;
               -  Higher grade AV block (i.e. 3rd degree)&#xD;
&#xD;
               -  Ventricular tachycardia (&gt;= 5 seconds of VT OR any symptomatic VT)&#xD;
&#xD;
          7. Atrial fibrillation with heart rate greater than 110 bpm.&#xD;
&#xD;
          8. Severe valvular disease (e.g. aortic stenosis of moderate or worse severity, valvular&#xD;
             insufficiency requiring surgical repair) or history of heart valve replacement.&#xD;
&#xD;
          9. Known allergy to porcine proteins or prior implantation of a porcine derived medical&#xD;
             product including cardiac valves or other ECM products.&#xD;
&#xD;
         10. Etiology of heart failure due to any cause (e.g. hypertrophic cardiomyopathies,&#xD;
             restrictive cardiomyopathies, constrictive pericardial disease, amyloidosis, active&#xD;
             myocarditis) other than the index MI.&#xD;
&#xD;
         11. Severe peripheral vascular disease that impairs femoral arterial access.&#xD;
&#xD;
         12. Less than 3 years, cancer free, since end of treatment for cancer (with exception of&#xD;
             basal cell carcinoma)&#xD;
&#xD;
         13. Alcohol or drug dependency within six months prior to enrollment&#xD;
&#xD;
         14. Cerebrovascular event within the 90 days prior or major surgical procedure or major&#xD;
             trauma within the 14 days prior to enrollment&#xD;
&#xD;
         15. Participation, defined as receiving test article, in an experimental clinical study&#xD;
             within 30 days prior to administration of VentriGel (i.e. screen failure from other&#xD;
             study does not exclude subject)&#xD;
&#xD;
         16. Uncontrolled hypertension defined as systolic blood pressure (SBP) &gt; 180 mmHg and/or&#xD;
             or diastolic blood pressure (DBP) &gt;110 mmHg&#xD;
&#xD;
         17. Abnormal laboratory values as defined below performed at screening:&#xD;
&#xD;
               -  Aspartate aminotransferase [AST]/ alanine aminotransferase [ALT] ≥ 3 times upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Serum creatinine ≥ 2.0 mg/dL&#xD;
&#xD;
               -  Platelet count &lt; 50,000/mm3&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g/dL&#xD;
&#xD;
               -  HbA1c &gt; 9.0%&#xD;
&#xD;
               -  PT or aPTT with clinically significant elevations relative to local laboratory&#xD;
                  norms&#xD;
&#xD;
         18. Any other cardiac or non-cardiac conditions or illness which, in the opinion of the&#xD;
             principal investigator, may place subjects at undue risk or compromise the objectives&#xD;
             of the study.&#xD;
&#xD;
         19. Institutional interpretation of cMR EF data outside the ≥ 25% and ≤ 45% limits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extracellular matrix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

